Table 2.
Between-Group Differences in Change ± SE After 2 Years, Adjusted for Baseline Measurement of Outcome
| Outcome | Alen/Alen v Alen/Placebo
|
Alen/Alen v Placebo/Alen
|
Alen/Placebo v Placebo/Alen
|
||||||
|---|---|---|---|---|---|---|---|---|---|
| Percentage Point Difference Change | SE | P | Percentage Point Difference Change | SE | P | Percentage Point Difference Change | SE | P | |
| PA spine | 3.79 | 1.22 | .002 | 4.66 | 1.07 | < .001 | 0.87 | 1.01 | .392 |
| Lateral spine | 4.97 | 2.13 | .021 | 4.64 | 1.98 | .020 | −0.33 | 1.87 | .862 |
| Femoral neck | 2.59 | 1.17 | .028 | 3.75 | 1.04 | < .001 | 1.16 | 1.00 | .247 |
| Trochanter | 0.67 | 0.99 | .500 | 1.92 | 0.89 | .032 | 1.25 | 0.82 | .131 |
| Total hip | 1.26 | 0.77 | .101 | 1.92 | 0.68 | .005 | 0.67 | 0.65 | .303 |
| One-third distal radius | 1.50 | 0.90 | .096 | 1.15 | 0.80 | .151 | −0.34 | 0.77 | .653 |
| Ultradistal radius | 2.34 | 0.98 | .018 | 2.90 | 0.86 | < .001 | 0.56 | 0.83 | .502 |
| Total distal radius | 2.25 | 0.68 | .001 | 2.07 | 0.60 | < .001 | −0.18 | 0.58 | .762 |
| Urine NTX | −20.43 | 20.28 | .315 | −14.36 | 17.78 | .420 | 6.08 | 17.33 | .726 |
| Serum CTX | −17.16 | 14.28 | .231 | −11.79 | 12.51 | .347 | 5.37 | 12.09 | .657 |
| BSAP | −12.83 | 13.30 | .335 | −5.53 | 11.62 | .634 | 7.31 | 11.20 | .515 |
| Osteocalcin | −16.85 | 8.26 | .042 | −10.22 | 7.22 | .158 | 6.63 | 6.97 | .342 |
| P1NP | −31.8 | 15.06 | .036 | −17.27 | 13.13 | .190 | 14.54 | 12.67 | .252 |
Abbreviations: Alen, alendronate; PA, posteroanterior; NTX, N-telopeptide crosslinks of type 1 collagen; BSAP, bone-specific alkaline phosphatase; CTX, C-telopeptide crosslinks of type 1 collagen; P1NP, N-terminal propeptide of type 1 procollagen.